Designing of an ELISA method for the measurement of serum antibodies against interferon-beta and the study of the frequency of these antibodies in patients with multiple sclerosis treated with CinnoVex

Nasrin Zare, Sayyed Hamid Zarkesh Esfahani, Vahid Shaygannejad, Marjan Gharagozloo

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. Interferon-beta (IFN-β) was the first disease modifying drug to be approved for the treatment of MS. Some MS patients treated with IFN-β develop antibodies to the drug. Anti-IFN-β antibodies can reduce both bioactivity and clinical efficacy of IFN-β. The objective of this study was to develop an enzyme-linked immunosorbent assay (ELISA) method for the measurement of anti-IFN-β antibodies in MS patients treated with CinnoVex (a recombinant Interferon beta 1-a). Methods: An Indirect ELISA protocol was developed and validated for the measurement of anti-IFN-β antibodies. Sera were studied for anti-IFN-β antibodies from 40 healthy individuals and 42 MS patients treated with CinnoVex for at least 6 months. Findings: Patients were considered positive for Anti-IFN-β antibodies, if they had a positive sample with an optical density of more than 1.2. Anti-IFN-β antibodies were found in 12 MS patients treated with CinnoVex. 31.1% of MS patients treated with CinnoVex developed anti-IFN-β antibodies. Conclusion: ELISA is a simple, fast and inexpensive test for the assessment of anti-IFN-β antibodies in MS patients treated with IFN-β.

Original languageEnglish (US)
Pages (from-to)1481-1491
Number of pages11
JournalJournal of Isfahan Medical School
Volume30
Issue number207
StatePublished - Dec 2012
Externally publishedYes

Keywords

  • Antibodies
  • Enzyme-linked immunosorbent assay
  • Interferon beta 1a
  • Multiple sclerosis

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Designing of an ELISA method for the measurement of serum antibodies against interferon-beta and the study of the frequency of these antibodies in patients with multiple sclerosis treated with CinnoVex'. Together they form a unique fingerprint.

Cite this